Our Research

Research
Houston Methodist COVID-19 Research Thumbnail
Coronavirus Disease 2019 (COVID-19) Research

Houston Methodist researchers are studying the novel coronavirus disease 2019. Read more...

At Houston Methodist, fostering innovations with the potential for clinical application is at the very heart of what we do. Our interdisciplinary teams of clinicians and researchers are committed to streamlining the process of translating discoveries into treatments and cures for our patients.

 

Learn more about how we are delivering on our commitment to leading medicine from the earliest phase of discovery in a lab to the testing new drugs or therapies in clinical trials.

 

Our VIEW BOOK



You can find our most recent annual report here: 2023 HMAI Annual Report

Novel medical technology for craniomaxillofacial surgery is cleared by FDA for market

Doctor using AnatomicAligner, a new FDA-approved Methodist-built software program, on an iPad.

Houston Methodist recently reached a major milestone, receiving U.S. Food and Drug Administration (FDA) 510(k) clearance to market the AnatomicAligner, a novel, comprehensive software program used to improve planning for craniomaxillofacial (CMF) surgeries. Learn more>

Houston Methodist is first to treat COVID-19 with convalescent plasma therapy

Computer-generated image of a Coronavirus

Houston Methodist was the first in the nation to receive FDA approval to use convalescent plasma for COVID-19 patients and the first to publish a peer-reviewed study on the therapy, revealing 19 of 25 critically ill patients showed improvement. Learn more>

 

Researchers Identify Protein To Aid With Glioblastomas

Molecular Analysis Slide

In a recent study published in Nature Communications, Houston Methodist researchers, led by Kyuson Yun, PhD, associate professor of neurology, conducted a molecular analysis that identified a protein, S100A4, which could be a therapeutic target for restoring anti-tumor action of immune cells toward glioblastomas that have beguiled the immune system into protecting it.  Learn more>

Center for RNA Therapeutics Awarded Inno Fire Award

Inno Fire Awards Logo

The Center for RNA Therapeutics won the 2022 Houston Inno Fire Award from the Houston Business Journal for innovation in health care and life sciences. Learn more>

 

Latest News

Friday, April 17, 2026 Blood pressure drug effective for treating antibiotic-resistant bacteria according to Houston Methodist researchers
Infections from antibiotic-resistant bacteria are difficult to treat and are responsible for over 2.8 million infections and more than 35,000 deaths in the U.S. each year. A new study in Nature Communications reports that a drug used to lower blood pressure could also be the basis of a promising new...
Read more
Thursday, April 16, 2026 Houston Methodist study finds newly developed AI-powered tool helps identify drugs to target antibiotic-resistant bacteria
A newly-designed AI-powered tool is effective in developing treatments to target antibiotic-resistant bacteria by breaking down their outer defenses, according to new research from Houston Methodist.   The study, published in Nature Communications and led by Eleftherios Mylonakis, M.D., Ph.D., chair...
Read more
Monday, March 16, 2026 This Unexpected Symptom May Be A Sign You Have The Flu
Read more
View All News & Events
More to Explore
Find Faculty
Find Core Facilities
Explore Faculty Labs